The 36-month beta value for TPST is also noteworthy at -1.66. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TPST is 39.62M, and at present, short sellers hold a 7.90% of that float. The average trading volume of TPST on January 31, 2025 was 1.67M shares.
TPST) stock’s latest price update
Tempest Therapeutics Inc (NASDAQ: TPST) has seen a rise in its stock price by 0.13 in relation to its previous close of 0.94. However, the company has experienced a -0.41% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-06 that BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ antagonist for the treatment of patients with hepatocellular carcinoma (HCC).
TPST’s Market Performance
Tempest Therapeutics Inc (TPST) has seen a -0.41% fall in stock performance for the week, with a 12.90% gain in the past month and a -13.98% plunge in the past quarter. The volatility ratio for the week is 6.95%, and the volatility levels for the past 30 days are at 9.02% for TPST. The simple moving average for the past 20 days is 2.46% for TPST’s stock, with a -45.34% simple moving average for the past 200 days.
Analysts’ Opinion of TPST
Many brokerage firms have already submitted their reports for TPST stocks, with Scotiabank repeating the rating for TPST by listing it as a “Sector Outperform.” The predicted price for TPST in the upcoming period, according to Scotiabank is $13 based on the research report published on March 14, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see TPST reach a price target of $15. The rating they have provided for TPST stocks is “Buy” according to the report published on February 08th, 2024.
TPST Trading at 6.96% from the 50-Day Moving Average
After a stumble in the market that brought TPST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.23% of loss for the given period.
Volatility was left at 9.02%, however, over the last 30 days, the volatility rate increased by 6.95%, as shares surge +13.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.75% upper at present.
During the last 5 trading sessions, TPST fell by -0.01%, which changed the moving average for the period of 200-days by -71.56% in comparison to the 20-day moving average, which settled at $0.9237. In addition, Tempest Therapeutics Inc saw 13.39% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TPST starting from Versant Venture Capital VI, L., who proposed sale 387,999 shares at the price of $1.10 back on Aug 12 ’24. After this action, Versant Venture Capital VI, L. now owns shares of Tempest Therapeutics Inc, valued at $426,993 using the latest closing price.
Versant Venture Capital VI, L., the 10% Owner of Tempest Therapeutics Inc, sale 400,000 shares at $1.35 during a trade that took place back on Aug 08 ’24, which means that Versant Venture Capital VI, L. is holding 597,940 shares at $540,040 based on the most recent closing price.
Stock Fundamentals for TPST
The total capital return value is set at -1.79. Equity return is now at value -691.89, with -122.85 for asset returns.
Based on Tempest Therapeutics Inc (TPST), the company’s capital structure generated 0.61 points at debt to capital in total, while cash flow to debt ratio is standing at -1.64. The debt to equity ratio resting at 1.55. The interest coverage ratio of the stock is -24.63.
Currently, EBITDA for the company is -28.78 million with net debt to EBITDA at 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.69.
Conclusion
In summary, Tempest Therapeutics Inc (TPST) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
